A new trading day began on Friday, with Rockwell Medical Inc (NASDAQ: RMTI) down -9.09% from the previous day of trading, before settling in for the closing price of $1.21. RMTI’s price has ranged from $0.78 to $5.15 over the past 52 weeks.
A company in the Healthcare sector has jumped its sales by 66.71% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -483.33%. With a float of $28.91 million, this company’s outstanding shares have now reached $34.43 million.
Rockwell Medical Inc (RMTI) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Rockwell Medical Inc is 15.94%, while institutional ownership is 17.11%. The most recent insider transaction that took place on Oct 01 ’25, was worth 3,413. In this transaction SVP, Chief Operating Officer of this company sold 2,868 shares at a rate of $1.19, taking the stock ownership to the 135,391 shares. Before that another transaction happened on Oct 01 ’25, when Company’s Officer proposed sale 886 for $1.15, making the entire transaction worth $1,017.
Rockwell Medical Inc (RMTI) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 0.05 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -483.33% per share during the next fiscal year.
Rockwell Medical Inc (NASDAQ: RMTI) Trading Performance Indicators
Here are Rockwell Medical Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.43. Likewise, its price to free cash flow for the trailing twelve months is 14.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.07, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.13 in one year’s time.
